Search

Your search keyword '"Basalious, Emad B."' showing total 178 results
Start Over Author "Basalious, Emad B."
178 results on '"Basalious, Emad B."'

9. Advancements in current one-size-fits-all therapies compared to future treatment innovations for better improved chemotherapeutic outcomes: a step-toward personalized medicine.

Author

Hamdy, Nadia M., Basalious, Emad B., El-Sisi, Mona G., Nasr, Maha, Kabel, Ahmed M., Nossier, Eman S., and Abadi, Ashraf H.

Subjects
*TARGETED drug delivery, *GENOME editing, *INDIVIDUALIZED medicine, *GENE therapy, *MEDICAL personnel
Abstract

The development of therapies followed a generalized approach for a long time, assuming that a single treatment could effectively address various patient populations. However, recent breakthroughs have revealed the limitations of this one-size-fits-all paradigm. More recently, the field of therapeutics has witnessed a shift toward other modules, including cell therapies, high molecular weight remedies, personalized medicines, and gene therapies. Such advancements in therapeutic modules have the potential to revolutionize healthcare and pave the way for medicines that are more efficient and with minimal side effects. Cell therapies have gained considerable attention in regenerative medicine. Stem cell-based therapies, for instance, hold promise for tissue repair and regeneration, with ongoing research focusing on enhancing their efficacy and safety. High molecular weight drugs like peptides and proteins emerged as promising therapeutics because of their high specificity and diverse biological functions. Engineered peptides and proteins are developed for targeted drug delivery, immunotherapy, and disease-modulation. In personalized medicine, tailored treatments to individuals based on specific genetic profiling, lifestyle, biomarkers, and disease characteristics are all implemented. Clinicians have tailored treatments to optimize outcomes and minimize adverse effects, using targeted therapies based on specific mutations, yielding remarkable results. Gene therapies have revolutionized the treatment of genetic disorders by directly targeting the underlying genetic abnormalities. Innovative techniques, such as CRISPR-Cas9 have allowed precise gene editing, opening up possibilities for curing previously incurable conditions. In conclusion, advancements in therapeutic modules have the potential to revolutionize healthcare and pave the way for medicines that are more efficient and with minimal side effects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques

Author

Hamdy,Nadia M, Eskander,Georgette, and Basalious,Emad B

Subjects
International Journal of Nanomedicine
Abstract

Nadia M Hamdy,1,* Georgette Eskander,2,* Emad B Basalious3,* 1Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt; 2Faculty of Pharmacy, Ain Shams University, Postgraduate Student, Cairo, Egypt; 3Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt*These authors contributed equally to this workCorrespondence: Emad B Basalious; Nadia M Hamdy, Email Emad.basalious@pharma.cu.edu.eg; nadia_hamdy@pharma.asu.edu.egAbstract: Anti-cancer conventional chemotherapeutic drugs novel formula progress, nowadays, uses nano technology for targeted drug delivery, specifically tailored to overcome therapeutic agents’ delivery challenges. Polymer drug delivery systems (DDS) play a crucial role in minimizing off-target side effects arising when using standard cytotoxic drugs. Using nano-formula for targeted localized action, permits using larger effective cytotoxic doses on a single special spot, that can seriously cause harm if it was administered systemically. Therefore, various nanoparticles (NPs) specifically have attached groups for targeting capabilities, not seen in bulk materials, which then need activation. In this review, we will present a simple innovative, illustrative, in a cartoon-way, enumeration of NP anti-cancer drug targeting delivery system activation-types. Area(s) covered in this review are the mechanisms of various NP activation techniques.Graphical Abstract: Keywords: intrinsic-activation, extrinsic-activation, NPs, nanoparticles, DDS, drug delivery systems, cancer biology, nano-bio-medicine

Published
2022

21. Integrated nanovesicular/self-nanoemulsifying system (INV/SNES) for enhanced dual ocular drug delivery: statistical optimization, in vitro and in vivo evaluation

Author

Yousry, Carol, Zikry, Pakinam M., Salem, Heba M., Basalious, Emad B., and El-Gazayerly, Omaima N.

Abstract

Ocular drug administration is usually problematic and suffers low bioavailability due to several physiological and biological factors that hinder their effective treatment. Terconazole (TZ) is considered as one of the effective ocular antifungal agents that is usually administrated intravitreally for higher efficacy. The aim of the work in this study is to formulate a TZ-loaded ocular drug delivery system with high efficiency and good tolerability. First, TZ-loaded bile-based nanovesicles (BBNV) were prepared and the formulation variables (namely, Span 60, cholesterol, and sodium deoxycholate levels) were optimized based on the results of the entrapment efficiency (EE%), particle size (PS), and zeta potential (ZP) using Box-Behnken statistical design. The optimized system was formulated using 73.59 mg Span 60, 1.28 mg cholesterol, and 3.11 mg sodium deoxycholate. The formulated system showed vesicles with PS of 526 nm, − 42.2 mV ZP, and 93.86% EE%. TZ release, cellular uptake, and cytotoxicity of the optimized system were evaluated in vitro. In addition, in vivo assessment of its safety was conducted histopathologically and via ocular irritation test to ensure the ocular tolerance of the system. Afterwards, the optimized TZ-loaded BBNV was integrated into a self-nanoemulsifying system (SNES) to allow faster TZ release for immediate antifungal effect, enhanced ocular residence, and improved ocular permeation. TZ release study revealed more than 2 folds increment in drug release rate from the integrated system compared to BBNV alone. Finally, this integrated system was assessed for its antifungal activity in vivo where it demonstrated higher antifungal activity against induced Candida albicansinfection.

Published
2024
Full Text
View/download PDF

22. Multi-Epitope Vaccine Design against Monkeypox Virus via Reverse Vaccinology Method Exploiting Immunoinformatic and Bioinformatic Approaches

Author

Bhattacharya, Kunal, primary, Shamkh, Israa M., additional, Khan, Mohammad Shahbaz, additional, Lotfy, Marwa M., additional, Nzeyimana, Jean Bosco, additional, Abutayeh, Reem Fawaz, additional, Hamdy, Nadia M., additional, Hamza, Dalia, additional, Chanu, Nongmaithem Randhoni, additional, Khanal, Pukar, additional, Bhattacharjee, Atanu, additional, and Basalious, Emad B., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results